Scientists will work side-by-side in MedImmune labs, aiming to speed research and development of new therapies
CELLINK, focused on the development and commercialization of innovative bioprinting technologies, announced today that the company will enter a year-long collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, providing 3D-Bioprinted tissues to aid in the exploration of new disease targets in MedImmune’s core therapeutic areas, including oncology, respiratory, and cardiovascular, renal and metabolic diseases.
The collaboration will leverage CELLINK’s innovative and patent-pending bioink, which enables human cells to grow and thrive as they would in the human body. CELLINK will provide a small team of experts to be embedded with MedImmune scientists in the biotech’s Gaithersburg, MD facility. MedImmune will provide expertise in early stage discovery process, antibody and protein engineering and optimization, as well as a real-time opportunity to evolve the CELLINK technology based on needs and applications of scientists in the lab.
“This collaboration would further open the Pharmaceutical development segment for CELLINK and lay the groundwork for future drug development processes. MedImmune is a leader in biologics research and development and embraces cutting-edge technology to advance the development of potential new therapies. It’s an honor and a tremendous opportunity for us to work side-by-side with MedImmune” said Erik Gatenholm, CEO, CELLINK
Dr. Herren Wu, Chief Technology Officer and Global Head of Antibody Discovery and Protein Engineering at MedImmune, said: “We’re looking forward to utilizing not only CELLINK’s innovative technology, but also their direct expertise in our labs. From biotech to high-tech, collaboration is core to how we operate and to opening new doors for the potential discovery of new therapies.”
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: +46 73 267 00 00 Phone: +46 70 991 86 04
This information is the one that CELLINK AB is required to publish under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on December 4th at. 08:45.
CELLINK is the first bioink company in the world and the leading 3Dbioprinter provider that focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic treatments. Founded 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. To read more about CELLINK, please visit: www.cellink.com CELLINK is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.